Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer

Oncogene

Volumn 33, Issue 27, 2014, Pages 3594-3603

  Munro, S ^a   Oppermann, U ^b   La Thangue, N B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cancer; DP 1; E2F; somatic mutation

Indexed keywords

AMINO ACID; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CELL CYCLE PROTEIN 6; CYCLIN E; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; HETERODIMER; PROTEIN P73; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CRYSTAL STRUCTURE; CYTOPLASM; DATA MINING; DIMERIZATION; DNA BINDING; DNA DAMAGE; DNA HELIX; FRAMESHIFT MUTATION; GROWTH INHIBITION; HCT116 CELL LINE; HELA CELL LINE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MISSENSE MUTATION; MUTANT; NONSENSE MUTATION; PLEIOTROPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SAOS 2 CELL LINE; SOMATIC MUTATION; STEREOSPECIFICITY; TRANSCRIPTION INITIATION; U2OS CELL LINE;

AMINO ACID SEQUENCE; APOPTOSIS; CELL LINE, TUMOR; E2F1 TRANSCRIPTION FACTOR; GENETIC PLEIOTROPY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHOPROTEINS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN SUBUNITS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR DP1;

EID: 84903892207     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.316     Document Type: Article

References (42)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
2. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053-1061.
3. Stevens C, La Thangue NB. E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 2003; 412: 157-169.
4. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3: 11-20.
5. Bandara LR, Lathangue NB. Adenovirus-E1a prevents the retinoblastoma gene-product from complexing with a cellular transcription factor. Nature 1991; 351: 494-497.
6. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
7. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 2004; 117(Pt 11): 2173-2181.
8. Kohn MJ, Bronson RT, Harlow E, Dyson NJ, Yamasaki L. Dp1 is required for extra-embryonic development. Development 2003; 130: 1295-1305.
9. Kohn MJ, Leung SW, Criniti V, Agromayor M, Yamasaki L. Dp1 is largely dispensable for embryonic development. Mol Cell Biol 2004; 24: 7197-7205.
10. Polager S, Ginsberg D. E2F-at the crossroads of life and death. Trends Cell Biol 2008; 18: 528-535.
11. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
12. Blattner C, Sparks A, Lane D. Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 1999; 19: 3704-3713.
13. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003; 5: 401-409.
14. Biswas AK, Johnson DG. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 2012; 72: 13-17.
15. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738-748.
16. Yu W, Chan-On W, Teo M, Ong CK, Cutcutache I, Allen GE et al. First somatic mutation of E2F1 in a critical DNA binding residue discovered in well-differentiated papillary mesothelioma of the peritoneum. Genome Biol 2011; 12: R96.
17. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000; 96: 73-92.
18. Sellers WR, Kaelin Jr WG. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15: 3301-3312.
19. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 2004; 91: 355-358.
20. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
21. Zheng N, Fraenkel E, Pabo CO, Pavletich NP. Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev 1999; 13: 666-674.
22. de la Luna S, Burden MJ, Lee CW, La Thangue NB. Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal. J Cell Sci 1996; 109(Pt 10): 2443-2452.
23. Magae J, Wu CL, Illenye S, Harlow E, Heintz NH. Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J Cell Sci 1996; 109(Pt 7): 1717-1726.
24. Nevins JR. Transcriptional regulation. A closer look at E2F. Nature 1992; 358: 375-376.
25. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/S-regulatory genes. Mol Cell Biol 1995; 15: 4215-4224.
26. Rubin SM, Gall AL, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 2005; 123: 1093-1106.
27. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 2003; 5: 552-558.
28. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 2001; 15: 1833-1844.
29. Lee TA, Farnham PJ. Exogenous E2F expression is growth inhibitory before, during, and after cellular transformation. Oncogene 2000; 19: 2257-2268.
30. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
31. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393-2409.
32. Yamasaki L. Role of the RB tumor suppressor in cancer. Cancer Treat Res 2003; 115: 209-239.
33. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 1997; 94: 7245-7250.
34. DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 2006; 6: 739-748.
35. Bandara LR, Buck VM, Zamanian M, Johnston LH, La Thangue NB. Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F. EMBO J 1993; 12: 4317-4324.
36. Bandara LR, Lam EW, Sorensen TS, Zamanian M, Girling R, La Thangue NB. DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the ade-novirus E4 orf 6/7 protein. EMBO J 1994; 13: 3104-3114.
37. Milton A, Luoto K, Ingram L, Munro S, Logan N, Graham AL et al. A functionally distinct member of the DP family of E2F subunits. Oncogene 2006; 25: 3212-3218.
38. Hateboer G, Wobst A, Petersen BO, Le Cam L, Vigo E, Sardet C et al. Cell cycle-regulated expression of mammalian CDC6 is dependent on E2F. Mol Cell Biol 1998; 18: 6679-6697.
39. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3: 552-558.
40. Botz J, Zerfass-Thome K, Spitkovsky D, Delius H, Vogt B, Eilers M et al. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 1996; 16: 3401-3409.
41. Markham D, Munro S, Soloway J, O'Connor DP, La Thangue NB. DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep 2006; 7: 192-198.
42. Munro S, Khaire N, Inche A, Carr S, La Thangue NB. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene 2010; 29: 2357-2367.